#USA #Washington #Clinical Trial #CathWorks #FFRangio

Groundbreaking Clinical Trial Shows CathWorks FFRangio Matches Traditional PCI Outcomes

In an unexpected turn of events for cardiovascular care, a substantial clinical trial presented at the Cardiovascular Research Technologies (CRT) conference in Washington, DC has validated the efficacy of CathWorks FFRangio technology. This study, led by Dr. Christopher Chieh Yang Koo from the National University Hospital Singapore, reports outcomes from the first-ever US cohort of over 4,000 patients treated with this innovative system.

Trial Overview and Objectives

The study analyzed Medicare outcomes data from 2019 to present, specifically utilizing angiography-derived physiology (ADP) assessments which demonstrated remarkable utility over traditional methods. With a focus on both inpatient and outpatient physiological assessments, the trial's major goal was to evaluate the cumulative incidence of major adverse cardiac events (MACE), which encompasses parameters such as death, myocardial infarction (MI), or repeat revascularization.

Between 2019 and 2024, the adoption of ADP showed an impressive growth, nearing eightfold. Participants included 1,591 patients in the PCI group who underwent both ADP and invasive pressure wire assessments, alongside 2,532 non-PCI patients also undergoing both types of evaluations.

Key Findings

The findings revealed that the cumulative incidence of MACE at two years was strikingly similar between the two patient groups: 24.8% for ADP and 23.5% for the invasive pressure wire in the PCI group, highlighting a hazard ratio (HR) of 1.01. For non-PCI patients, the figures were 24.1% for ADP and 23.9% for traditional wire methods, with a corresponding HR of 0.97. These statistics suggest no significant disadvantage with the use of FFRangio technology compared to traditional methods.

Dr. Eric A. Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center, remarked on the significance of these outcomes. “This first look at contemporary data on the growing adoption of ADP shows similar clinical events including mortality, MI, and revascularization through two years, when compared with invasive approaches. Given promising secondary outcomes such as reduced resource utilization and a strong clinical evidence base, we expect ADP's adoption rate to accelerate,” he stated.

Further reinforcing these findings, Ramin Mousavi, President and CEO of CathWorks, underscored how this large-scale cohort study contributes to establishing a robust evidence foundation for CathWorks FFRangio. He emphasized that ongoing innovations within their platform streamline its clinical integration without compromising patient outcome quality.

The Promise of CathWorks FFRangio

CathWorks is positioned at the forefront of digital health innovations, aiming to elevate the standard of cardiac care through advanced technology integration. The FFRangio® System significantly alters the approach to diagnosing cardiovascular diseases by leveraging artificial intelligence and routine angiograms to gather physiological insights, mitigating the necessity for invasive techniques and drug-induced stimulation.

This trial's promising results could compel healthcare institutions to rethink current practices regarding physiological assessments in coronary artery disease diagnosis, potentially establishing CathWorks FFRangio as the new standard in cardiology. As noted in the published study of the trial results in Circulation Cardiovascular Interventions, further scrutiny of varying technologies will remain essential in ensuring optimal patient care.

In summary, the trial highlighted by this groundbreaking presentation not only showcases CathWorks FFRangio's current efficacy but also heralds its future as a transformative instrument in cardiovascular intervention and patient management. For more on CathWorks and their innovative approaches, visit CathWorks Website and follow their updates on LinkedIn.